Krystal Biotech, Inc.

KRYS Nasdaq SEC CIK 1711279
Follow Krystal Biotech Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $127.3M +30.2% vs same quarter last year
Net income $63.1M −20.5% vs same quarter last year
EPS, diluted $2.05 −22.9% vs same quarter last year
Operating cash flow $91.2M +130.1% vs same quarter last year
Revenue by quarter
$91.1M
$88.2M
$96M
$97.8M
$107.1M
$116.4M
$119.2M
$127.3M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income10 fiscal years
  • Revenue
  • Net income
−$200M$0$200M$400MFY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$389.1M$204.8M
FY24$290.5M$89.2M
FY23$50.7M$10.9M
FY22$0−$140M
FY21$0−$69.6M
FY20-−$32.2M
FY19-−$19.1M
FY18-−$10.9M
FY17-−$7.9M
FY16-−$1.2M
MarginsShare of revenue
  • Operating margin
  • Net margin
−300%−200%−100%0%100%FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY2541.5%52.6%
FY2422.6%30.7%
FY23−216.2%21.6%
FY22--
FY21--
FY20--
FY19--
FY18--
FY17--
FY16--
Free cash flowOperating cash flow minus capital expenditure
−$200M−$100M$0$100M$200MFY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25$188.9M
FY24$119.2M
FY23−$100.6M
FY22−$153.5M
FY21−$116.3M
FY20−$40.9M
FY19−$25.1M
FY18−$11.7M
FY17−$4.1M
FY16−$1.3M
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Krystal Biotech
  • Healthcare median
−100%−50%0%50%100%FY17FY19FY21FY23FY25
Show the numbers
YearKrystal BiotechHealthcare median
FY2552.6%−30.6%
FY2430.7%−47%
FY2321.6%−58%
FY22-−80.4%
FY21-−71.8%
FY20-−62.2%
FY19-−46.2%
FY18-−49.6%
FY17-−45.9%
FY16-−36%